| Home | E-Submission | Sitemap | Contact Us |  
top_img
J Korean Cancer Assoc > Volume 26(5); 1994 > Article
Journal of the Korean Cancer Association 1994;26(5): 786-793.
전신기 소세포 폐암에 대한 EP 화학요법과 EP / CAV 교대화학요법의 비교 연구
허대석, 방영주, 김노경, 박영석, 서창인, 정기석
A Randomized Comparison of EP Sequential Chemotherapy Versus EP / CAV Alternating Chemotherapy for Extencive - stage Small - cell Lung Cancer
Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim, Young Suk Park, Chang In Suh, Ki Suck Chang
ABSTRACT
The present randomized, prospective study was designed to assess whether alternating etoposide, cisplatin (EP) and cyclophosphamide, adriamycin, vincristine (CAV) is better than etoposide, cisplatin (EP) chemotherapy in improving response, survival and remission duration in 62 evaluable patients having extensive-stage small-cell lung cancer.(SCLC) There were no significant differences in treatment outcome for EP alone, EP/CAV in terms of response rate (65/ versus 75%), complete response rate (9% versus 7%), remission duration (5 months versus 5 months) or median survival (10 months versus 1 l months). Severe myelosuppressian was more common in EPiCAV alternating treatment. The EP/CAV alternating regimen and EP alone regimen can be considered equivalently effective induction therapies in extensive SCLC and these two regimens are, to some degree, cross resistant. Alternating therapy provides no therapeutic advantage with more myelosuppression compared to the EP alone chemotherapy and should not be considered as standard treatment in this clinical setting.
Key words: Small cell lung cancer, combination chemotherapy
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI